Pfizer has started construction on its new $200M biologics clinical manufacturing plant in Andover, Massachusetts.
The 16,300sq m five-storey facility will enable the production of complex biologics and vaccines.
According to Pfizer, the new facility is designed with five independent manufacturing suites to support its complex and diverse biologics research effort.
The plant will implement flexible design to fully enable next generation manufacturing strategies, use the latest single-use bioreactors and disposable process technologies and provide clinical manufacturing options with the lowest cost and greatest flexibility for efficiently driving important clinical drugs to patients.
Senator Barbara L’Italien said: “This five-storey building will add 75 new permanent manufacturing jobs and 200 temporary construction jobs to Pfizer’s Andover campus, already home to 1,200 employees.”
The plant is expected to be operational by January 2019.
* Data provided by Timetric's Construction Intelligence Center.